Innoviva, Inc. (NASDAQ: INVA) is a Healthcare company (Biotechnology) with a market capitalization of $1.3B. The Maz Rating grades it against the other companies in its sector.
Innoviva, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $18.36, Innoviva, Inc. trades at 7.2x trailing earnings, 3.0x sales and 1.2x book value, with an EV/EBITDA of 1.7. Over the last twelve months it generated about $442M of revenue and $181M of net income. It runs a gross margin of 73.9%, an operating margin of 38.5% and a net margin of 43.8%. It shows return on equity of 15.8%, return on invested capital of 9.9% and a free cash flow yield of 13.9%. On the balance sheet: a debt-to-equity ratio of 0.24 and a current ratio of 15.44. Over the past 52 weeks the share price ranged from $18.30 to $25.15, with a beta of 0.33.
Innoviva, Inc. does not currently pay a dividend.
11 Wall Street analyst ratings cover the stock: 6 Buy, 4 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.